← Back to Search

Monoclonal Antibodies

NC318 + Pembrolizumab for Lung Cancer

Phase 2
Recruiting
Led By Scott Gettinger
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically documented, locally advanced or metastatic NSCLC
At least one tumor amenable to biopsy, and willingness to undergo tumor biopsy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up tumor response will be based on tumor assessments at screening, every 8 weeks from the first dose (for the first 24 weeks) and thereafter every 12 weeks until investigator-assessed initial disease progression, up to 4 years
Awards & highlights

Study Summary

This trial is testing NC318, a new cancer drug, either alone or with another cancer drug, pembrolizumab, to see if it can treat advanced non-small cell lung cancer.

Who is the study for?
This trial is for adults with advanced non-small cell lung cancer who have tried PD-1 axis inhibitor therapy and it didn't work (except Arm 2a). They should be relatively healthy, able to undergo a biopsy, and not have used immunosuppressive drugs recently. Those with certain gene mutations after treatment failure or intolerance are also eligible.Check my eligibility
What is being tested?
The study is testing the effectiveness of NC318 at two different doses, either alone or combined with Pembrolizumab. It's designed to see how well these treatments can control lung cancer that has spread and isn't responding to previous therapies.See study design
What are the potential side effects?
Possible side effects include reactions related to the immune system attacking normal cells in the body, infusion-related reactions from receiving drugs through a vein, fatigue, potential organ inflammation, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung cancer is advanced or has spread to other areas.
Select...
I am willing to have a biopsy on at least one of my tumors.
Select...
I have had PD-1 inhibitor therapy and my cancer progressed afterwards.
Select...
I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~tumor response will be based on tumor assessments at screening, every 8 weeks from the first dose (for the first 24 weeks) and thereafter every 12 weeks until investigator-assessed initial disease progression, up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and tumor response will be based on tumor assessments at screening, every 8 weeks from the first dose (for the first 24 weeks) and thereafter every 12 weeks until investigator-assessed initial disease progression, up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants in arm 2 with treatment related adverse events as assessed by CTCAE v5
Number of participants in arm 2a with treatment related adverse events as assessed by CTCAE v5
Number of participants on Arm 1b with treatment related adverse events as assessed by CTCAE v5
+6 more
Secondary outcome measures
Overall Survival (RECIST v1.1) Arm 1a
Overall survival (RECIST v1.1) Arm 1B
Overall survival (RECIST v1.1) Arm 2
+3 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

5Treatment groups
Experimental Treatment
Group I: Arm 2a (naïve to PD-1 axis inhibitor)- NC318 and PembrolizumabExperimental Treatment2 Interventions
Arm 2a will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive combination therapy with NC318 and pembrolizumab.
Group II: Arm 2 (naïve to PD-1 axis inhibitor)- NC318 and PembrolizumabExperimental Treatment2 Interventions
Arm 2 will enroll patients with advanced NSCLC who are naïve to PD-1 axis inhibitor therapy to receive therapy with NC318 in combination with pembrolizumab.
Group III: Arm 1c - NC318 and PembrolizumabExperimental Treatment1 Intervention
At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
Group IV: Arm 1b - NC318 and PembrolizumabExperimental Treatment2 Interventions
At the discretion of the treating physician, advanced NSCLC patients on arm 1b will receive combination therapy with NC318 and pembrolizumab.
Group V: Arm 1a - NC318 onlyExperimental Treatment1 Intervention
At the discretion of the treating physician, advanced NSCLC patients on arm 1a will receive NC318 alone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,851 Previous Clinical Trials
2,738,054 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,662 Previous Clinical Trials
40,925,914 Total Patients Enrolled
NextCure, Inc.Industry Sponsor
6 Previous Clinical Trials
389 Total Patients Enrolled

Media Library

NC318 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04699123 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: Arm 2 (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab, Arm 2a (naïve to PD-1 axis inhibitor)- NC318 and Pembrolizumab, Arm 1a - NC318 only, Arm 1b - NC318 and Pembrolizumab, Arm 1c - NC318 and Pembrolizumab
Non-Small Cell Lung Cancer Clinical Trial 2023: NC318 Highlights & Side Effects. Trial Name: NCT04699123 — Phase 2
NC318 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04699123 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the main goals that researchers hope to achieve with this clinical trial?

"The sponsor of this clinical trial, Merck Sharp & Dohme LLC, has stated that the primary objective for this study will be to measure tumor response over time in patients with NSCLC who have progressed on prior anti-PD-1 therapy. This will be done by assessing tumors at screening and every 8 weeks for the first 24 weeks and then every 12 weeks until initial disease progression is observed. The secondary objectives of this trial include measuring progression-free survival RECIST v1.1), overall survival (RECIST v1.1), and overall survival (RECIST v1.1) in two different patient groups: those"

Answered by AI

Are there any more slots open for this experiment?

"That is correct. The clinical trial website has the most recent information on the status of this study, which is presently looking for 141 participants at 1 location."

Answered by AI

What are some of the conditions that Pembrolizumab is used to treat?

"Pembrolizumab is a medication that can be used to treat several different cancers. In addition, this drug can also help patients who are experiencing disease progression after chemotherapy or those with unresectable melanoma and microsatellite instability high."

Answered by AI

Could you give some examples of other research done on Pembrolizumab?

"Pembrolizumab is being trialled in 1000 separate studies, 122 of which are in Phase 3. Many of the Pembrolizumab trials are based out of Houston, Texas; however, there 36030 locations running these medical experiments."

Answered by AI

Will Pembrolizumab have any long-term negative effects on patients?

"Pembrolizumab is a Phase 2 medication, which means that while there is some evidence to support its safety, there is none yet for efficacy. We've given it a score of 2."

Answered by AI

How many human test subjects are a part of this clinical research?

"That is accurate, the website provides information that this study is looking for participants. The trial was posted on February 4th 2021 and updated on May 9th 2022. There is one site where 141 people will be enrolled in the trial."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Scott Gettinger, MD 2021. "The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04699123.
~41 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top